ResearcherAsan Medical CenterNo recent work listed
Inhwan Hwang
Matched on OpenAlex author ID A5103822214. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2018: 1 paper · 2019: 1 paper · 2020: 2 papers
Papers 4
- FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. First author DOI 10.1177/1758835920953294↗
- Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
- Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammat… Co-author DOI 10.1007/s10637-018-0681-y↗
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. First author DOI 10.1007/s10637-018-0598-5↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kyu‐pyo Kim · 4 shared papers, 2018–2020 · strength 0.35
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Baek‐Yeol Ryoo · 4 shared papers, 2018–2020 · strength 0.35
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Changhoon Yoo · 4 shared papers, 2018–2020 · strength 0.35
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Do Hyun Park · 3 shared papers, 2018–2020 · strength 0.24
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Tae Jun Song · 3 shared papers, 2018–2020 · strength 0.24
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Myung‐Hwan Kim · 3 shared papers, 2018–2020 · strength 0.24
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Sang Soo Lee · 3 shared papers, 2018–2020 · strength 0.24
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. DOI 10.1177/1758835920953294↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Jin‐hong Park · 2 shared papers, 2020 · strength 0.18
- JiHoon Kang · 2 shared papers, 2018–2019 · strength 0.16
- Paper Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel pl… DOI 10.1007/s10637-018-0681-y↗
- Paper Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreati… DOI 10.1007/s10637-018-0598-5↗
- Ki Byung Song · 2 shared papers, 2018–2020 · strength 0.15
- Dae Wook Hwang · 2 shared papers, 2018–2020 · strength 0.15
- Dong Wan Seo · 2 shared papers, 2018–2020 · strength 0.15
- Song Cheol Kim · 2 shared papers, 2018–2020 · strength 0.15
- Kyunghye Bang · 1 shared paper, 2020 · strength 0.09
- Kyoungmin Lee · 1 shared paper, 2020 · strength 0.09
- Dongwook Oh · 1 shared paper, 2020 · strength 0.09
- Woohyung Lee · 1 shared paper, 2020 · strength 0.09
- Jae Ho Byun · 1 shared paper, 2020 · strength 0.09
- Sang Hyun Shin · 1 shared paper, 2018 · strength 0.06
- Seung‐Mo Hong · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.